Search General Info
Search Education
Search Partnering Companies
Primmune Therapeutics, Inc.
2:45 PM - 3:00 PM (EST), Tuesday, February 7, 2023 ・ Palace
![CEO 2023 Logo](/sites/default/files/2022-08/264423_BIO_22_CEO_Logo-V.png)
Primmune Therapeutics is developing PRTX007 as a systemic oral innate immune therapy for solid tumors (adjuvant/combo w/CPIs) and as single agent therapy for clearance of HPV driven cervical pre-cancerous lesions and infections.
We recently completed a large healthy volunteer phase I SAD/MAD study (n = 130) with PRTX007 dosed orally on a continuous basis.
PRTX007's safety, tolerability, PK and innate/adaptive immune PD data were as we predicted based on our extensive PO in vivo primate and in vitro hPBMC studies.
PRTX007 is a novel oral systemically acting TLR7 agonist that drives a very well tolerated AUC dependent poly-IFN response (via IRF7) with no meaningful NFKB pro-inflammatory cytokines activity.
In addition to stimulating clinically meaningful ISG and chemokine/cytokine responses; PRTX007 also drove meaningful systemic T and NK cell activation/proliferation. In murine tumor models, PRTX007 also demonstrated synergistic T-Cell increases in the TME w/ CPIs
We recently completed a large healthy volunteer phase I SAD/MAD study (n = 130) with PRTX007 dosed orally on a continuous basis.
PRTX007's safety, tolerability, PK and innate/adaptive immune PD data were as we predicted based on our extensive PO in vivo primate and in vitro hPBMC studies.
PRTX007 is a novel oral systemically acting TLR7 agonist that drives a very well tolerated AUC dependent poly-IFN response (via IRF7) with no meaningful NFKB pro-inflammatory cytokines activity.
In addition to stimulating clinically meaningful ISG and chemokine/cytokine responses; PRTX007 also drove meaningful systemic T and NK cell activation/proliferation. In murine tumor models, PRTX007 also demonstrated synergistic T-Cell increases in the TME w/ CPIs
![](/sites/default/files/hubb_images/6588/attachments/%2520-%2520f1_Primmune_20Therapeutics_00483528.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Oncology
Lead Product in Development:
PRTX007
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
![photo](/sites/default/files/hubb_images/6588/photos/user1.McDermott.04d55b47.jpeg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved